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Whole blood is currently being reintroduced as a blood product to be used in
massive bleeding situations because it affords plasma, red cells and platelets in a
balanced ratio and in a logistical advantageous way. Questions concerning the
haemostatic potential of the platelets have arisen, especially in cold-stored whole
blood, as this is the major whole blood product in use. When reviewing current
knowledge on this, there is an abundance of publications demonstrating that
in vitro, platelets in cold-stored whole blood have a haemostatic capacity up to
14 days, and even after 21 and 35 days of storage depending on type of additive
solution. There is a paucity of data on clinical trials of cold-stored platelets,
whereas there is an abundance of previous clinical experience with whole blood,
both cold-stored and fresh, as an efficacious and safe product for use in pre- and
in-hospital patients with life-threatening bleeding.
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Introduction
Whole blood (WB) as a blood product for direct patient
use has virtually been absent for 40 years in the practice
of transfusion medicine in high-income countries of the
world. It is now back in vogue particularly in clinical sit-
uations of damage control resuscitation and haemostatic
resuscitation [1–3]. With this revival renewed concerns
on its use have arisen, namely availability, blood group
to be utilized, haemolytic impact of antibodies in plasma,
leucoreduction, infections, red cell and platelet function-
ality. To minimize risks of untoward reactions, group 0
WB with a low titre of anti-A and anti-B is recommended
[4–7]. Some also remove leucocytes, but spare blood pla-
telets [8]. Concerns have been raised about lack of plate-
let-mediated haemostatic function in whole blood,
particularly after prolonged cold storage, but conversely,
also worries about increased thrombotic potential.
When addressing platelet function the term ‘viability’ of
platelets is frequently used, usually pertaining to the sur-
vival or recovery of transfused donor platelets in the
patient. It may also refer to platelet longevity in the blood
bank storage facility as measured by in vitro aspects like
metabolic activity, secretion of cytokines, aggregation
ability or shape change. However, when considering plate-
let function in case of bleeding patients, this term should
refer to the actual in vivo haemostatic ability.
This review highlights platelet functionality in whole
blood as measured by laboratory experiments and clinical
investigations.
WB defined
Whole Blood is collected from a donor by phlebotomy of
450–-500  50 ml blood into a plastic bag containing an
anticoagulant solution and stored under varying conditions,
see Table 1. Cold-stored whole blood, CWB, can be stored at
1–6°C for up to 21 days if the anticoagulant is CPD, or
35 days if the anticoagulant contains adenine (e.g. CPDA-1),
however, the storage time is defined by investigations of red
cell survival and not platelet function. WB for transfusion is
used without further processing; however, leucocyte-de-
pleted whole blood (WB-LD) is preferred within some regula-
tory domains (e.g. Europe < 10 x 106/l leucocytes) to
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reduces risk of WBC-induced transfusion reactions [9]. Leu-
coreduction can be performed by use of a platelet-sparing
(PS) or non-platelet-sparing (NPS) filter. Using a NPS filter
has the obvious disadvantage of loosing the platelets essen-
tial for the haemostatic effects of WB, whereas using a PS
filter retain platelet concentration and function within
required limits (J Sivertsen, H Braathen, THF Lunde, et al.,
submitted) [10]. Currently, only one PS filter is commercially
available (IMUFLEX WB-SP, Terumo BCT; Lakewood, CO,
USA). According to European Guidelines, WB should con-
tain a minimum of 45 g haemoglobin (43 g for WB-LD) and
show less than 0.8% haemolysis at the end of storage [9].
If CWB is used before 48 h following collection, it may
be called cold ‘fresh’ WB (CFWB). In some situations, WB
may be used shortly after donation and is then called warm
fresh WB, WFWB. WFWB may be stored at room tempera-
ture (20°C) for up to 8 h, and subsequently at 4°C for 16 h
[11]. These time restraints are probably more related to the
subsequent harvest of plasma than functional aspects of
WFWB [12]. WFWB has traditionally been used in neonatal
open-heart surgery or in remote austere settings where
other blood products are unavailable.
The transfusion of WB is subject to risk of the same
kind of adverse transfusion-related reactions as when
transfusing red cell concentrates. Likewise, as for plasma
and platelet concentrate transfusions, blood group anti-
body and citrate toxicity must be considered when WB is
transfused. When WB is used fresh, the risk of transfu-
sion-associated graft-versus-host disease (TA-GVHD) is
perceived to be higher than when transfusing red cell or
platelet concentrates. TA-GVHD has been reported in one
military patient receiving WB, although HLA-typing of
the patient and donor did not seem to imply the WB [13].
TA-GVHD may be mitigated by irradiation [14].
PLT functionality defined
‘Viability’ is the term usually coined when describing the
function of platelets. The term refers to the ability of
transfused platelets to remain in circulation [15], which is
an important factor in prophylactic platelet transfusions.
The ability to circulate is, however, of less interest in
clinical situations with ongoing bleeding. In the latter,
the immediate haemostatic ability of platelets is of pri-
mary interest. Platelet haemostatic function involves sev-
eral phenomena; extent of shape change, aggregation,
activation, receptor expression and binding of coagula-
tion factors, to name some. The sum of these phenomena
defines the platelet functionality. This can be measured
by a multitude of in vitro laboratory methods such as
aggregometry (e.g. Chrono-log, Multiplate), viscoelastic
tests (thromboelastography (TEG) and thromboelastometry
(RoTEM)), flow cytometry (expression of different surface
markers either spontaneous or agonist-induced), measures
of membrane integrity (phosphatidylserine externaliza-
tion, cytosolic esterase induced fluorescence), electron
microscopy, heat-shock resistance, shear-stress (PFA-100),
shape changes and microvesicle formation. For several of
these tests, the actual platelet concentration will influence
the results. The different types of platelet functional tests
have been reviewed elsewhere [16,17].
However, even though the in vitro tests result in pre-
cise and quantifiable parameters, they do not translate
directly to clinical efficacy. Measurements of platelet
effects in vivo include assessments of bleeding grade by
standardized bleeding scores, standardized measurements
of bleeding time, quantification of bleeding volume, total
use of blood products, survival and recovery of radiola-
belled platelets. The in vivo efficacy of platelets should be
evaluated in prospective, preferably randomized, clinical
trials. Although these are time-consuming and expensive
to perform, they yield high-quality data. When evaluating
the clinical effect of platelet transfusion, several blood
component and patient-related factors might influence
the measured haemostatic effects of transfusion. The pla-
telet component factors include the content of platelet
and plasma, storage duration, and pre-storage production
methods that may influence on platelet function. Patient-
related factors may include concentration of red cells and
leucocytes in the circulation, the interaction with the
Table 1 Variants of whole blood for transfusion
Storage time Storage temp°C Leucoreduction Anticoagulant additive
WFWB 8 h 20 Optional depending on anticoagulant additive CPD/CP2D/CPDA-1
Followed by 16 h at 4
CWB 21 days 4 Frequentlya CPD/CP2D
35 day 4 No CPDA-1
CFWB 48 h 4 Optional depending on anticoagulant additive CPD/CP2D/CPDA-1
CFWB, cold-stored fresh whole blood; CPD, citrate-phosphate-dextrose; CP2D, citrate-phosphate-double dextrose; CPDA-1, citrate-phosphate-dextrose-
adenine; CWB, cold-stored whole blood; WFWB, warm fresh whole blood.
aLeucoreduction with platelet-sparing filter.
© 2019 The Authors. ISBT Science Series published by John Wiley & Sons Ltd on behalf of
International Society of Blood Transfusion., ISBT Science Series (2019) 14, 308–314
Platelet functionality in whole blood 309
endothelial lining, and the clinical condition (ongoing
bleeding, coagulation disorders, anti-platelet drugs, fever,
etc.).
Functionality of platelets in vitro and in vivo
The in vitro functionality of CWB platelets
The physiology of cold-stored platelets has recently been
reviewed [18]. Storing platelets in the cold causes struc-
tural, molecular, and metabolic changes, which is often
referred to as the cold platelet storage lesion [18]. Cold-s-
tored platelets show signs of activation and are thought
to be ‘primed’ and ready to participate in the haemostatic
process. The in vitro functions of platelets in CWB have
been evaluated by many researchers, and they generally
confirm that significant haemostatic functionality remains
at least beyond 14 days of storage and for some labora-
tory test even longer (J Sivertsen, H Braathen, THF Lunde,
et al., submitted) [8,10,11]. The results are, however,
dependent on method of preparation, additive solution
(CPD or CPDA-1) and type of test used (J Sivertsen, H
Braathen, THF Lunde, et al., submitted) [8,19].
When subjecting CWB to thromboelastographic/-metric
analysis (TEG/RoTEM) researcher have generally found
that most test parameters stay within normal ranges after
14 and even 21 days of cold storage [8,10,20,21]. This is
also the case for stored CWB that was leucoreduced using
a platelet-sparing filter (IMUFLEX WB-SP, Terumo BCT,
US)[8,10,11,21,22], while TEG tracings of WB-NonPS
were grossly abnormal due to the absence of platelets
[21,23]. This has been corroborated in blood collection
bags with adenine added to the anticoagulant solution
(CPDA-1) [11]. The IMUFLEX WB-SP leucoreduction fil-
ter seems to perform similarly for both CPDA-1 and CPD
with respect to the removal of leucocytes and also for the
haemostatic function of platelets (J Sivertsen, H Braathen,
THF Lunde, et al., submitted); [10] however, the effects of
leucoreduction on platelet function are under debate [24].
When evaluated in pathogen reduced WB by use of the
Mirasol System with or without leucocyte removal,
pathogen reduction, especially in combination with leuco-
cyte removal, reduces haemostatic function [24,25]. The
effect of different types of anticoagulants (CPD, CP2D,
CPDA-1) in CWB on platelet function have been investi-
gated revealing little impact on haemostatic functionality
[19]. Interestingly, mixing CWB at expiry date with fresh
whole blood improve coagulation responses and platelet
function as measured by RoTEM [19].
Platelet aggregation in CWB evaluated by shear forces
(PFA-100) also maintained aggregation for 14 days when
leucoreduced with platelet-sparing methods but not when
platelets were removed [21]. Aggregation evaluated by
agonist-induced aggregation is reduced, but persistent,
beyond day 10 [10,20,24–26]. Using a novel flow cytome-
try-based platelet aggregation method Sperling et al. [20]
found that platelets from CWB (non-leucoreduced) stored
for up to 21 days performed at least as well as both buffy
coat and apheresis platelets (room-temperature storage
for 7 days) when subjected to a panel of various platelet
stimulators. Pidcoke et al. [25] compared warm and cold
storage of WB with or without pathogen reduction for
21 days and found that for CWB shear-induced aggrega-
tion was increased compared to WFWB.
As room-temperature platelet concentrates are stored
using continual horizontal agitation in order to avoid
aggregation, concerns have been raised pertaining to the
mechanical storage conditions of CWB. Groups have
looked at daily manual mixing, continual rotational mix-
ing vs. no mixing. Some publications show platelet
counts to decrease during storage by up to 50%, whereas
others show no significant differences on platelet num-
bers even at day 21 [10,22,27]. This discrepancy may
reflect differences in pre-sampling manipulation. How-
ever, little differences on in vitro platelet functional tests
were found [10,22,26–28].
The in vivo functionality of CWB platelets
The haemostatic function of platelets in CWB has been
reported from case studies, retrospective studies, observa-
tional prospective studies and randomized clinical trials.
The transfusion of CWB to massively bleeding patients
started more than 100 years ago [29,30], and after a per-
iod of absence is now returning to military medicine
[5,31,32], indeed as the preferred military transfusion pro-
duct [33–35]. Descriptive reports on the effect of fresh
and stored whole blood transfusion have been published,
mainly from military operations [36–40],but also civilian
reports are being published [41–45].
A randomized controlled trial performed by Manno
and colleagues in paediatric patients undergoing cardiac
surgery showed reduced blood loss and improved platelet
function by aggregometry after transfusion with 24–48 h
cold-stored whole blood when compared to component-
based therapy with room-temperature platelets [46]. By
radiolabelling studies, Slichter and colleagues have shown
that CWB stored for up to 15 days have similar post-stor-
age platelet viability [47] as the FDA approved 3-day-old
cold-stored platelet concentrates [48]. The authors con-
clude that platelet yields, post-storage platelet recoveries
and survivals, and platelet function should be sufficient
to support the short-term haemostatic needs of trauma-
tized patients [27].
Warm fresh whole blood is considered to have full
haemostatic function [46], especially when given early in
© 2019 The Authors. ISBT Science Series published by John Wiley & Sons Ltd on behalf of
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resuscitation [39] and is considered to be superior to
CWB [49] and room-temperature-stored platelets (RTP)
[50,51]. It has routinely been used in open-heart surgery
of the newborn [46], although it may not confer any
advantage over reconstituted blood (packed red blood
cells and fresh frozen plasma) in priming the cardiopul-
monary bypass circuit [52]. Currently, its use is mostly
limited to situations when other blood products are
unavailable, either in austere remote situations, or where
blood bank inventory (particularly of platelet concen-
trates) is depleted [42]. Time constraints may necessitate
the use of WFWB from pretested donors with test for
transfusion transmittable infectious diseases performed
after use as recently reported [42].
The functionality of cold-stored platelets in
plasma or platelet additive solutions
There is an abundance of publications, old and more
recent, on cold-stored platelet, CSP, concentrates either in
plasma of platelet additive solutions from both in vitro
and in vivo perspectives. It was early recognized that pla-
telet survival and recovery was decreased when stored
cold [15], but the superior aggregation potential of CSPs
was also recognized early [53–55]. Valeri demonstrated
the greater potential of CSP to reverse aspirin-induced
platelet defect in healthy subjects compared to RTP. The
in vitro CSP haemostatic potential has more recently been
confirmed and elaborated using an expanding palette of
methods by several groups [56–64], and has even been
found on prolonged storage up to 18–21 [57,63]. The
importance of maintaining a minimum level of glucose
has been demonstrated raising the question to increase
the plasma concentrations in CSP or perhaps store plate-
lets in WB [57,65]. Data from in vitro experiments indi-
cate that platelet haemostatic ability is better in WB than
in WB reconstituted from components [49], and may also
outperform platelet concentrates [54], even after extended
storage [20].
The potential functions and use of CSP was recently
reviewed elsewhere [62],but recent in vivo studies of CSP
are still few. Clinical use of 3 days CSP has started in the
US in 2015, but did initially have challenges with aggre-
gates in the CSPs probably due to lack of PAS[66]. Pre-
liminary results from a recently concluded randomized
pilot trial by our group comparing CSP to RTP, either
stored for up to 7 days in PAS, indicate that CSP is at
least as effective in treating postoperative bleeding in
patients undergoing complicated open cardiac surgery
with no increased risk of adverse events [67] The outcome
measures of the study were postoperative bleeding and
platelet haemostatic functions (aggregation and throm-
boelastography/metry), but also number of blood products
transfused. Encouraged by these findings, we have
extended the study with an arm of 14 days CSP storage
[68].
Discussion
Based on the experiences from recent military conflict
most civilian trauma programs to day include the use of
massive transfusion protocols [69,70]. Early balanced
transfusion is recommended, and most centres still use
components to mimic as closely as possible a 1:1:1 ratio.
However, concerns have been raised on the probable infe-
riority of a reconstituted product when it comes to plate-
let activity, coagulation factor loss, haemoglobin
concentration and the significant dilatory effect of addi-
tives [71]. Therefore, more civilian trauma centres are
switching to CWB as their preferred blood product in
massively bleeding patients (D Jenkins, personal commu-
nication, 2019) [1,72–74]. CWB has been in uninterrupted
routine use in the developing low to medium income
economies around the world, even though the targeted
use of blood components is increasing, particularly
packed red cells used for normovolaemic patients with
severe anaemia. However, as clinical situations with mas-
sive bleeding (especially traffic accidents, shooting, stab-
bings and peripartum haemorrhage) is common in many
low- to medium income countries of the world, a com-
plete conversion to a component-based transfusion prac-
tice is not advantageous neither from a medical nor from
an economic perspective. Providing a balanced transfu-
sion in massive bleeding situations requires more
resources with a component strategy compared to using
WB, especially in providing platelets. Realizing this, the
Blood Transfusion Service of Zanzibar, Tanzania, has
implemented a Massive Transfusion Protocol that includes
the forward storage and resupply of several units uncross-
matched low titre group 0 WB in the operating theatres
of the maternity ward for use in critical obstetric bleeding
situations [75]. This intervention has so far assisted in
saving numerous lives and serves as an example for
obstetrical wards and trauma centres elsewhere.
Conclusions
For decades, CWB was the only platelet-containing pro-
duct available for the treatment of massive bleeding and
was considered an effective and safe intervention, espe-
cially when using only group 0 WB. In vitro tests of pla-
telet functionality in WB uniformly demonstrate that
within commonly used storage and time constraints, pla-
telets are highly functional. Publications on the in vivo
functionality of platelets in CWB are few, but those that
are leaves little doubt of the effectiveness of platelets.
© 2019 The Authors. ISBT Science Series published by John Wiley & Sons Ltd on behalf of
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But, we do not know how long platelet haemostatic func-
tionality is preserved in the clinical setting. And,
although logistically superior, we still need to find out
whether WB improves outcome in a hospital setting com-
pared to a well-balanced component transfusion practice.
In the aftermath of the re-introduction of CWB in both
pre-hospital as well as in-hospital protocols of massive
transfusion, more evidence will emerge in the near future.
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